Literature DB >> 9283926

Placebo-controlled treatment trial of depression in elderly physically ill patients.

M Evans1, M Hammond, K Wilson, M Lye, J Copeland.   

Abstract

OBJECTIVES: To determine the response of physically ill elderly depressed patients to treatment.
DESIGN: Acute geriatric medical inpatients with depression, randomly assigned to an 8-week double-blind placebo-controlled trial of fluoxetine. MAIN OUTCOME MEASURE: Response rate as defined by the 17-item Hamilton Depression Rating Scale.
RESULTS: Eighty-two patients entered the trial; 62 patients (all those who had completed at least 3 weeks of treatment) were included in the efficacy analysis. Forty-two completed the full 8 weeks (21 in each group) with response rates of 67% in the fluoxetine group and 38% in the placebo group. No significant difference was found between the responses of the two groups (p = 0.12). There was a trend for results in the fluoxetine group to continue to improve with time. On secondary analysis those patients with serious physical illness who completed 5 or more weeks (N = 37) showed a significant improvement in mood if treated with fluoxetine (p = 0.02).
CONCLUSIONS: The main benefit of antidepressants is to approximately double the chances of recovery. This trial showed the response rate of the fluoxetine treated group was increased by a factor of 1.8 over the placebo group in an 8-week period. The presence of physical illness, often severe and/or multiple, did not reduce the effectiveness of the medication, which was well tolerated overall. Those with serious physical disease responded significantly better to drug treatment; this will require further work. Psychological support was also considered to be important.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9283926     DOI: 10.1002/(sici)1099-1166(199708)12:8<817::aid-gps645>3.0.co;2-4

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  13 in total

1.  Antidepressants for old people. GPs should become familiar with one or two antidepressants from each class.

Authors:  R C Baldwin
Journal:  BMJ       Date:  1999-09-25

Review 2.  Care of older people: Mental health problems.

Authors:  A Burns; T Dening; R Baldwin
Journal:  BMJ       Date:  2001-03-31

3.  New antidepressants for old people?

Authors:  M G Livingston; H M Livingston
Journal:  BMJ       Date:  1999-06-19

Review 4.  Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis.

Authors:  Winfried Rief; Yvonne Nestoriuc; Anna von Lilienfeld-Toal; Imis Dogan; Franziska Schreiber; Stefan G Hofmann; Arthur J Barsky; Jerry Avorn
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 5.  Pharmacological treatment of depression in older patients with chronic obstructive pulmonary disease: impact on the course of the disease and health outcomes.

Authors:  A M Yohannes; G S Alexopoulos
Journal:  Drugs Aging       Date:  2014-07       Impact factor: 3.923

Review 6.  Antidepressant versus placebo for depressed elderly.

Authors:  K Wilson; P Mottram; A Sivanranthan; A Nightingale
Journal:  Cochrane Database Syst Rev       Date:  2001

Review 7.  Anxiety and depression-Important psychological comorbidities of COPD.

Authors:  Marsus I Pumar; Curt R Gray; James R Walsh; Ian A Yang; Tricia A Rolls; Donna L Ward
Journal:  J Thorac Dis       Date:  2014-11       Impact factor: 2.895

Review 8.  Impact of medical comorbid disease on antidepressant treatment of major depressive disorder.

Authors:  Dan V Iosifescu; Bettina Bankier; Maurizio Fava
Journal:  Curr Psychiatry Rep       Date:  2004-06       Impact factor: 5.285

Review 9.  Time course of response to antidepressants in late-life major depression: therapeutic implications.

Authors:  Ellen M Whyte; Mary Amanda Dew; Ariel Gildengers; Eric J Lenze; Ashok Bharucha; Benoit H Mulsant; Charles F Reynolds
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

10.  A pulmonary rehabilitation program reduces levels of anxiety and depression in COPD patients.

Authors:  Athanasios Tselebis; Dionisios Bratis; Argiro Pachi; Georgios Moussas; Ioannis Ilias; Maria Harikiopoulou; Elpida Theodorakopoulou; Silvia Dumitru; Epaminondas Kosmas; Alexandros Vgontzas; Nikolaos Siafakas; Nikolaos Tzanakis
Journal:  Multidiscip Respir Med       Date:  2013-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.